References
- Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
- Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
- Chanan-Khan A, Czuczman MS, Padmanabhan S, et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. Blood 2007;110(Suppl. 1): 914A (Abstract 3108).
- Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85–88.
- Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519–2525.
- Chen CI, Paul H, Xu W, et al. Safety and efficacy of slow dose escalation of lenalidomide for frontline treatment in chronic lymphocytic leukemia (CLL) - results of a phase II study. Haematologica 2009;94:S93.
- Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047.
- Maddocks K, Lapalombella R, Blum KA, et al Preliminary results of a phase I study of lenalidomide in relapsed chronic lymphocytic leukemia. Blood 2009;114(Suppl.1):1339 (Abstract 3446).
- Wendtner CM, Mahadevan D, Stilgenbauer S, et al Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. Blood 2008;112(Suppl. 1): 732 (Abstract 2104).
- Badoux XC, Wierda WG, O'Brien SM, et al Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S93.
- Gao H, Ferrajoli A, Cohen EN, et al Treatment with lenalidomide has a positive immunomodulatory effect in patients with chronic lymphocytic leukemia. Blood 2008;112(Suppl. 1): 733 (Abstract 2107).
- Brown JR, Abramson JS, Hochberg EP, et al A phase I study of lenalidomide in combination with fludarabine-rituximab in previously untreated CLL/SLL. Blood 2009;114(Suppl. 1): 1330 (Abstract 3426).
- Brown JR, Abramson JS, Hochberg EP, et al A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Haematologica 2009;94:S86.
- Egle A, Steurer M, Melchardt T, Stoll M, Greil R. The REVLIRIT CLL5 AGMT Study - a phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated CLL: results of a planned interim analysis. Blood 2009;114(Suppl. 1): 1341 (Abstract 3453).
- Ferrajoli A, Badoux XC, O'Brien S, et al Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): 89 (Abstract 206).
- Lapalombella R, Andritsos L, Liu Q, et al Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood 2010;115:2619–2629.
- Aue G, Njuguna N, Tian X, et al Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266–1273.
- James D, Avery ED, Zhang L, et al Lenalidomide administered for the initial treatment of CLL patients - in vivo modulation of the leukemia cell surface phenotype and association with tumor flare reaction (TFR). Blood 2009;114(Suppl. 1): 1336 (Abstract 3440).